Two-way Road of Kidney and Hypercalcemia: A Narrative Review

Overview

Journal Cardiovasc Hematol Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Cardiology & Vascular Diseases
Hematology
Pharmacology

Date 2022 Dec 7

PMID 36475333

Authors

Ziba Aghsaeifard

Reza Alizadeh

Affiliations

Soon will be listed here.

Abstract

Calcium homeostasis is regulated by the dyad of parathyroid hormone and calcitriol, whereas kidney, intestine, and bone are the primary target sites. Elevation of serum calcium levels and hypercalcemia are likely markers of pathological conditions, particularly malignancy and hyperparathyroidism. Similarly, several dysfunctions within the body can direct hypercalcemia. Furthermore, chemicals and drugs can also drive this condition. Owing to the significant role of the kidney in calcium homeostasis, renal abnormalities lead to hypercalcemia and increased calcium levels can have pathological effects on the kidney. This review is designed to highlight some of the commonly known causes of hypercalcemia and their effects on the kidney.

References

Mirrakhimov A . Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci. 2015; 7(11):483-93. PMC: 4683803. DOI: 10.4103/1947-2714.170600. View

Alzahrani A, Sinnert R, Gernsheimer J . Acute kidney injury, sodium disorders, and hypercalcemia in the aging kidney: diagnostic and therapeutic management strategies in emergency medicine. Clin Geriatr Med. 2012; 29(1):275-319. DOI: 10.1016/j.cger.2012.10.007. View

Clines G . Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes. 2011; 18(6):339-46. DOI: 10.1097/MED.0b013e32834b4401. View

Felsenfeld A, Levine B, Rodriguez M . Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin Dial. 2015; 28(6):564-77. DOI: 10.1111/sdi.12411. View

Figueres M, Linglart A, Bienaime F, Allain-Launay E, Roussey-Kessler G, Ryckewaert A . Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis. 2014; 65(1):122-6. DOI: 10.1053/j.ajkd.2014.06.037. View

Khaleel A, Wu M, Wong H, Hsu Y, Chou Y, Chen H . A Single Nucleotide Polymorphism (rs4236480) in TRPV5 Calcium Channel Gene Is Associated with Stone Multiplicity in Calcium Nephrolithiasis Patients. Mediators Inflamm. 2015; 2015:375427. PMC: 4452106. DOI: 10.1155/2015/375427. View

Vezzoli G, Scillitani A, Corbetta S, Terranegra A, Dogliotti E, Guarnieri V . Risk of nephrolithiasis in primary hyperparathyroidism is associated with two polymorphisms of the calcium-sensing receptor gene. J Nephrol. 2014; 28(1):67-72. DOI: 10.1007/s40620-014-0106-8. View

Vargas-Poussou R, Mansour-Hendili L, Baron S, Bertocchio J, Travers C, Simian C . Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences. J Clin Endocrinol Metab. 2016; 101(5):2185-95. DOI: 10.1210/jc.2015-3442. View

Mastromatteo E, Lamacchia O, Campo M, Conserva A, Baorda F, Cinque L . A novel mutation in calcium-sensing receptor gene associated to hypercalcemia and hypercalciuria. BMC Endocr Disord. 2014; 14:81. PMC: 4197257. DOI: 10.1186/1472-6823-14-81. View

10.

Muirhead N, Zaltman J, Gill J, Churchill D, Poulin-Costello M, Mann V . Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transplant. 2013; 28(2):161-5. DOI: 10.1111/ctr.12291. View

11.

Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K . A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014; 14(11):2545-55. DOI: 10.1111/ajt.12911. View

12.

Jo H, Han K, So Y, Jun H, Han S . Effect of Cinacalcet in Kidney Transplant Patients With Hyperparathyroidism. Transplant Proc. 2019; 51(5):1397-1401. DOI: 10.1016/j.transproceed.2019.01.141. View

13.

OCallaghan S, Yau H . Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr Connect. 2020; 10(1):R13-R24. PMC: 7923058. DOI: 10.1530/EC-20-0487. View

14.

Tzotzas T, Goropoulos A, Karras S, Terzaki A, Siolos A, Doumas A . Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment. Hormones (Athens). 2022; 21(1):171-176. DOI: 10.1007/s42000-021-00343-w. View

15.

Cruzado J, Moreno P, Torregrosa J, Taco O, Mast R, Gomez-Vaquero C . A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. J Am Soc Nephrol. 2015; 27(8):2487-94. PMC: 4978046. DOI: 10.1681/ASN.2015060622. View

16.

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T . Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients . Clin Nephrol. 2019; 92(1):1-8. DOI: 10.5414/CN109723. View

17.

Aghsaeifard Z, Alizadeh R, Bagheri N . Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch Physiol Biochem. 2020; 128(3):703-707. DOI: 10.1080/13813455.2020.1720742. View

18.

van den Broek D, Chang Y, Elliott J, Jepson R . Chronic Kidney Disease in Cats and the Risk of Total Hypercalcemia. J Vet Intern Med. 2017; 31(2):465-475. PMC: 5354036. DOI: 10.1111/jvim.14643. View

19.

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1):26-36. DOI: 10.1016/j.kint.2017.04.006. View

20.

Peng J, Li X, Zhang D, Chen J, Su Y, Smith S . Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 2014; 87(1):137-50. PMC: 4276728. DOI: 10.1038/ki.2014.226. View